During the past decade, University of North Carolina-Hillsborough Campus conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 2 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of North Carolina-Hillsborough Campus" #1 sponsor was "National Cancer Institute (NCI)" with 3 trials, followed by "Alliance for Clinical Trials in Oncology" with 2 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 2 trials sponsored, "Shire" with 2 trials sponsored and "Dana-Farber Cancer Institute" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of North Carolina-Hillsborough Campus" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator and "Canadian Cancer Trials Group (CCTG)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "University of North Carolina-Hillsborough Campus" are "Crohn's Disease" (2 trials), "Anatomic Stage II Breast Cancer AJCC v8" (1 trials), "Anatomic Stage IIA Breast Cancer AJCC v8" (1 trials), "Anatomic Stage IIB Breast Cancer AJCC v8" (1 trials) and "Anatomic Stage IIIA Breast Cancer AJCC v8" (1 trials). Many other conditions were trialed in "University of North Carolina-Hillsborough Campus" in a lesser frequency.

Most popular intervention types in "University of North Carolina-Hillsborough Campus" are "Drug" (7 trials), "Other" (4 trials), "Biological" (3 trials), "Procedure" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (2 trials), "Pembrolizumab" (2 trials), "Quality-of-Life Assessment" (2 trials), "Questionnaire Administration" (2 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of North Carolina-Hillsborough Campus" are 8 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "University of North Carolina-Hillsborough Campus". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of North Carolina-Hillsborough Campus, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of North Carolina-Hillsborough Campus, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".

University of North Carolina-Hillsborough Campus has several departments that took part in Clinical trials: "UNC Dermatology and Skin Cancer Center" - 12 trials, "UNC Hospitals Endoscopy Center at Meadowmont" - 5 trials, "UNC Orthopaedics" - 5 trials, "UNC Cancer Hospital Infusion Pharmacy" - 5 trials, "UNC Diabetes Care Center/Highgate Specialty Center" - 2 trials, "UNC Hospitals Emergency Department" - 2 trials